Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-89.09%
operating margin TTM
-92.72%
revenue TTM
2.07 Million
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -13.07 |
| peg ratio | -0.22 |
| price to book ratio | 5.60 |
| price to sales ratio | 12.57 |
| enterprise value multiple | -15.79 |
| price fair value | 5.60 |
profitability ratios | |
|---|---|
| gross profit margin | 116.3% |
| operating profit margin | -92.72% |
| pretax profit margin | -90.4% |
| net profit margin | -89.09% |
| return on assets | -31.62% |
| return on equity | -40.51% |
| return on capital employed | -37.26% |
liquidity ratios | |
|---|---|
| current ratio | 4.35 |
| quick ratio | 3.82 |
| cash ratio | 1.04 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | -383.06 |
| operating cycle | -268.36 |
| days of payables outstanding | -180.62 |
| cash conversion cycle | -87.75 |
| receivables turnover | 3.18 |
| payables turnover | -2.02 |
| inventory turnover | -0.95 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.05 |
| debt equity ratio | 0.06 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.06 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -5.74 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.66 |
| cash per share | 0.66 |
| operating cash flow per share | -0.59 |
| free cash flow operating cash flow ratio | 1.12 |
| cash flow coverage ratios | -5.74 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -8.20 |
Frequently Asked Questions
When was the last time Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported earnings?
Iovance Biotherapeutics, Inc. (IOVA) published its most recent earnings results on 06-08-2026.
What is Iovance Biotherapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)'s trailing twelve months ROE is -40.51%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Iovance Biotherapeutics, Inc. (IOVA) currently has a ROA of -31.62%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IOVA's net profit margin stand at?
IOVA reported a profit margin of -89.09% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IOVA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.35 in the most recent quarter. The quick ratio stood at 3.82, with a Debt/Eq ratio of 0.06.